Alkermes plc (NASDAQ: ALKS) kicked off on Tuesday, down -0.82% from the previous trading day, before settling in for the closing price of $24.39. Over the past 52 weeks, ALKS has traded in a range of $20.46-$32.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 10.61% over the past five years. While this was happening, its average annual earnings per share was recorded 90.93%. With a float of $166.76 million, this company’s outstanding shares have now reached $166.98 million.
Let’s look at the performance matrix of the company that is accounted for 2100 employees.
Alkermes plc (ALKS) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Alkermes plc is 1.45%, while institutional ownership is 105.35%. The most recent insider transaction that took place on Mar 18 ’24, was worth 292,740. In this transaction SVP, Chief Commercial Officer of this company sold 10,417 shares at a rate of $28.10, taking the stock ownership to the 65,911 shares. Before that another transaction happened on Feb 27 ’24, when Company’s VP, Finance (Interim PAO) sold 2,559 for $29.65, making the entire transaction worth $75,874. This insider now owns 7,717 shares in total.
Alkermes plc (ALKS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 90.93% per share during the next fiscal year.
Alkermes plc (NASDAQ: ALKS) Trading Performance Indicators
Take a look at Alkermes plc’s (ALKS) current performance indicators. Last quarter, stock had a quick ratio of 2.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.37. Likewise, its price to free cash flow for the trailing twelve months is 10.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.54, a number that is poised to hit 0.67 in the next quarter and is forecasted to reach 2.61 in one year’s time.
Technical Analysis of Alkermes plc (ALKS)
Alkermes plc (NASDAQ: ALKS) saw its 5-day average volume 1.72 million, a negative change from its year-to-date volume of 1.88 million. As of the previous 9 days, the stock’s Stochastic %D was 20.17%. Additionally, its Average True Range was 0.64.
During the past 100 days, Alkermes plc’s (ALKS) raw stochastic average was set at 10.78%, which indicates a significant decrease from 17.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 23.00% in the past 14 days, which was lower than the 37.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.28, while its 200-day Moving Average is $26.42. Nevertheless, the first resistance level for the watch stands at $24.40 in the near term. At $24.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $24.75. If the price goes on to break the first support level at $24.05, it is likely to go to the next support level at $23.90. Assuming the price breaks the second support level, the third support level stands at $23.70.
Alkermes plc (NASDAQ: ALKS) Key Stats
The company with the Market Capitalisation of 4.09 billion has total of 169,221K Shares Outstanding. Its annual sales at the moment are 1,663 M in contrast with the sum of 355,760 K annual income. Company’s last quarter sales were recorded 350,370 K and last quarter income was 36,830 K.
